ACETYLDIGITOXIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C43H66O14
Molecular Weight	806.9757
Optical Activity	UNSPECIFIED
Defined Stereocenters	20 / 20
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]4CC[C@@]5(C)[C@]([H])(CC[C@]6([H])[C@]5([H])CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

InChI

InChIKey=HPMZBILYSWLILX-UMDUKNJSSA-N

InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021648s004lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.medscape.com/viewarticle/842364

Digoxin is a cardiac glycoside derived from the purple foxglove flower. In 1785, the English chemist, botanist, and physician Sir William Withering published his findings that Digitalis purpurea could be used to treat cardiac dropsy (congestive heart failure; CHF). Digoxin has been in use for many years, but was not approved by the FDA for treatment of heart failure (HF) until the late 1990s. Another FDA indication for digoxin is atrial fibrillation (AF). Digoxin also has numerous off-label uses, such as in fetal tachycardia, supra-ventricular tachycardia, cor pulmonale, and pulmonary hypertension. Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also has Para sympathomimetic properties. By increasing vagal tone in the sinoatrial and atrioventricular (AV) nodes, it slows the heart rate and AV nodal conduction.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/potassium-transporting ATPase 39 Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19751721	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Heart failure 103 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021648s004lbl.pdf	Primary		Approved 8429	CRYSTODIGIN Approved Use In adults, digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation. (1). In pediatric patients with heart failure, digoxin increases myocardial contractility
Chronic atrial fibrillation 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021648s004lbl.pdf	Diagnostic		Approved 8429	CRYSTODIGIN Approved Use In adults, digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation. (1). In pediatric patients with heart failure, digoxin increases myocardial contractility

C_max

Value	Dose	Co-administered	Analyte	Population
1.76 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18823299/	0.25 mg 1 times / day steady-state, oral dose: 0.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: ETORICOXIB	ETORICOXIB	DIGITOXIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.32 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18823299/	0.25 mg 1 times / day steady-state, oral dose: 0.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DIGITOXIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
13.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18823299/	0.25 mg 1 times / day steady-state, oral dose: 0.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: ETORICOXIB	ETORICOXIB	DIGITOXIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18823299/	0.25 mg 1 times / day steady-state, oral dose: 0.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DIGITOXIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
9.5 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/914188/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DIGITOXIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.4 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/914188/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	DIGITOXIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.7 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/914188/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	DIGITOXIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.1 mg 1 times / day multiple, oral Studied dose Dose: 0.1 mg, 1 times / day Route: oral Route: multiple Dose: 0.1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/	healthy, 23 to 29 years n = 10 Health Status: healthy Age Group: 23 to 29 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/	Other AEs: Color blindness acquired... Other AEs: Color blindness acquired Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/
0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	Other AEs: Fatigue, Visual disorders NEC... Other AEs: Fatigue (53.1%) Visual disorders NEC (53.1%) Muscular weakness (45.8%) Nausea (45.2%) Anorexia (44.7%) Psychic disorder NOS (36.3%) Abdominal pain (36.3%) Dizziness (33%) Bad dreams (30.2%) Headache (25.1%) Diarrhoea (22.9%) Vomiting (22.3%) Pain retrosternal (5%) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/

AEs

AE	Significance	Dose	Population
Color blindness acquired		0.1 mg 1 times / day multiple, oral Studied dose Dose: 0.1 mg, 1 times / day Route: oral Route: multiple Dose: 0.1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/	healthy, 23 to 29 years n = 10 Health Status: healthy Age Group: 23 to 29 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/
Vomiting	22.3%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Diarrhoea	22.9%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Headache	25.1%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Bad dreams	30.2%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Dizziness	33%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Abdominal pain	36.3%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Psychic disorder NOS	36.3%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Anorexia	44.7%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Nausea	45.2%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Muscular weakness	45.8%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Pain retrosternal	5%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Fatigue	53.1%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Visual disorders NEC	53.1%	0.2 mg 2 times / day multiple, oral (mean) Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Co-administed with:: digoxin(0.05 mg; 2 tablets per day) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult n = 179 Health Status: unhealthy Condition: heart failure Age Group: adult Sex: M+F Population Size: 179 Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 788 OATP1B3 706	P-gp 1537

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/24754247/	yes [IC50 14.2 uM]
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/24754247/	yes [IC50 36 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21316177/; https://pubmed.ncbi.nlm.nih.gov/18080812/; https://pubmed.ncbi.nlm.nih.gov/11284449/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/17095614/

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA003PFS	https://www.aablocks.com/goods/Goods/detail?id=AA003PFS
AHH Chemical co.,ltd	MT-50144	http://www.ahhchemical.com/product/MT-50144.html
AK Scientific, Inc. (AKSCI)	Y0070	http://www.aksci.com/item_detail.php?cat=Y0070
Aaron Chemicals	AR003Q7K	http://www.aaronchem.com/71-63-6
Acorn PharmaTech	ACN-035831	http://www.acornpharmatech.com/
Alfa Chemistry	AP71636-B	https://reagents.alfa-chemistry.com/product/digitoxin-cas-71-63-6-15506.html
Alfa Chemistry	AP71636-A	https://reagents.alfa-chemistry.com/product/digitoxin-solution-cas-71-63-6-15505.html
Aurora Fine Chemicals LLC	A17.877.985	http://online.aurorafinechemicals.com/info?ID=A17.877.985
Aurora Fine Chemicals LLC	K05.570.447	http://online.aurorafinechemicals.com/info?ID=K05.570.447
BioSynth	Q-100791	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-100791.html
Chem Scene	CS-5502	http://www.chemscene.com/71-63-6.html
ChemFaces	CFN98535	http://www.chemfaces.com/natural/Digitoxin-CFN98535.html
ChemMol	99138549	http://www.chemmol.com/chemmol/99138549.html
Chemenu	CM110200	http://www.chemenu.com/products/CM110200
Chemspace	CSSS00026968232	https://chem-space.com/CSSS00026968232
DC Chemicals	DC37933	http://www.dcchemicals.com//product_show-Digitoxin.html
Enamine	Z1558290128	https://www.enaminestore.com/catalog/Z1558290128
Glentham Life Sciences	GC5627	http://www.glentham.com/products/product/GC5627/
LGC Standards	DRE-A12633800AL-100	https://www.lgcstandards.com/US/en/p/DRE-A12633800AL-100
LGC Standards	DRE-C12633800	https://www.lgcstandards.com/US/en/p/DRE-C12633800
Lab Network	LN01343864	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343864
MedChem Express	HY-B1357	https://www.medchemexpress.com/Digitoxin.html
MolPort	MolPort-001-742-606	https://www.molport.com/shop/molecule-link/MolPort-001-742-606
MuseChem	I004671	https://www.musechem.com/product/I004671.html
MuseChem	M050845	https://www.musechem.com/product/M050845.html
OChem	11973	http://www.ocheminc.com/index.php?act=psearch&pid=071D636
R&D Chemicals	825	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=7705
Sigma-Aldrich	BP855_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp855?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	D1800000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/d1800000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	D5878_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/d5878?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1199002_USP	https://www.sigmaaldrich.com/catalog/product/usp/1199002?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S526083	http://www.smolecule.com/products/s526083
TCI (Tokyo Chemical Industry)	D0542	http://www.tcichemicals.com/eshop/en/us/commodity/D0542/index.html
THE BioTek	bt-264686	https://www.thebiotek.com/product/inhibitors/bt-264686
eNovation Chemicals	D659640	https://www.enovationchem.com/ProductDetails.asp?ProductID=D659640
iChemical	EBD27273	http://www.ichemical.com/products/71-63-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-8291336831	https://mcule.com/MCULE-8291336831/
mcule	MCULE-9783596421	https://mcule.com/MCULE-9783596421/

PubMed

Title	Date	PubMed
Digitoxin induced cardiac necrosis and its inhibition.	1969	5384065
[Acute digitalic poisoning].	1970 Feb	5447167
[Spironolactone protection against experimental cardiopathy due to digitoxin, disodium phosphate and oil].	1970 Feb	4909201
Possible mechanism of the prevention of digitoxin toxicity by spironolactone in the mouse.	1971 Jan	5130149
Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides.	1974 Nov	4418514
Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.	1977 Dec	914999
Digitalis delirium: a reminder.	1980 Mar	7361148
Reversal of digitalis-induced mesenteric vasospasm by sodium nitroprusside.	1982 Feb	7059269
Study of the factors influencing cardiac growth. II. Digitoxin treatment and isoproterenol-induced cardiac hypertrophy in the rat.	1985	2436403
Effect of digitoxin on cardiac arrhythmias in hemodialysis patients.	1987 Nov 16	2447325
[Digitoxin-induced thrombocytopenia].	1993	8212711
Synthesis of 20-hydroxy-, 20-amino-, and 20-nitro-14-hydroxy-21-nor-5 beta,14 beta-pregnane C-3 glycosides and related derivatives: structure-activity relationships of pregnanes that bind to the digitalis receptor.	1993 Jan 8	8421289
Digitoxin medication and cancer; case control and internal dose-response studies.	2001	11532201
Treatment of congestive heart failure--current status of use of digitoxin.	2001	11525233
Adverse drug reaction monitoring--digitoxin overdosage in the elderly.	2001 Aug	11515708
Bidirectional tachycardia: two cases and a review.	2002 Aug	12145041
Bidirectional ventricular tachycardia due to digitalis intoxication.	2005 Feb	15674736
Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis?	2009 Oct	19446813
Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents.	2013	24124520
A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides.	2014 Apr	24275119
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.	2015 Jun	25752796

Patents

Sample Use Guides

In Vivo Use Guide

Age Oral Loading Dose, mcg/kg Premature: 20 - 30; Full-Term 25 - 35; 1 to 24 months 35 - 60; 2 to 5 years 30 - 45; 5 to 10 years 20 - 35; Over 10 years 10 - 15

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

ACETYLDIGITOXIN

Official Name

English

ACETYLDIGITOXIN [MART.]

Common Name

English

(3.BETA.,5.BETA.)-3-((O-3-O-ACETYL-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-14-HYDROXYCARD-20(22)-ENOLIDE

Common Name

English

Acetyldigitoxin [WHO-DD]

Common Name

English

ACETYLDIGITOXINS .ALPHA.-FORM

Common Name

English

ACETYLDIGITOXINS .ALPHA.-FORM [MI]

Common Name

English

acetyldigitoxin [INN]

Common Name

English

ACYLANID

Brand Name

English

ACETYLDIGITOXIN [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC01AA01